mAIbe and LenioBio Join Forces to Innovate Monoclonal Antibody Development
In a significant advancement within the biopharmaceutical industry, mAIbe and LenioBio have announced a new strategic collaboration focused on enhancing the discovery and experimental validation of next-generation monoclonal antibodies. This partnership merges mAIbe's advanced AI-driven platform for antibody design and optimization with LenioBio's innovative cell-free expression technology, creating a powerful synergy aimed at streamlining the research and development process for therapeutic antibodies.
With mAIbe's cutting-edge artificial intelligence capabilities guiding the design of monoclonal antibodies, the integration of LenioBio’s high-throughput, scalable expression system allows for the swift production of complex antibodies necessary for high-quality experimental data. This framework supports the experimental analysis by feeding valuable data back into mAIbe's AI models, thereby enhancing the efficiency and accuracy of antibody development.
The initial phases of the collaboration will focus on accelerating the functional testing of candidate antibodies generated through AI. This approach not only fosters faster validation of these candidates but also facilitates rapid iterations between computational predictions and experimental outcomes. Such a streamlined process lays the groundwork for achieving unprecedented speeds in therapeutic antibody discovery.
The collaboration promises to set a new benchmark in the field, emphasizing agility and innovation through data-driven methodologies. By effectively bridging the gap in lab-based design workflows, mAIbe and LenioBio are poised to introduce a transformative impact on the landscape of antibody development.
About LenioBio: Established in Germany in 2016, LenioBio GmbH specializes in cell-free protein expression through its proprietary ALiCE® platform, which enables rapid protein discovery, development, and scalable production. Headquartered in Düsseldorf, the company operates state-of-the-art R&D and manufacturing facilities in Aachen. To learn more, visit www.leniobio.com or follow LenioBio on LinkedIn.
About mAIbe: Based in Rome, Italy, mAIbe focuses on the design of monoclonal antibodies using AI-driven techniques, combining generative AI informed by physical and synthetic biology principles. The firm is dedicated to developing precise and cost-effective antibodies targeting viral and bacterial pathogens, thereby accelerating the availability of next-generation immunotherapies. For further insights, visit www.maibe.eu.
As the collaboration unfolds, the scientific community eagerly anticipates the breakthrough developments that may arise from this merger of technology and biology. By leveraging each other’s strengths, mAIbe and LenioBio are not just competing in the market but rather setting the stage for future innovation in therapeutic antibody discovery.
With mAIbe's cutting-edge artificial intelligence capabilities guiding the design of monoclonal antibodies, the integration of LenioBio’s high-throughput, scalable expression system allows for the swift production of complex antibodies necessary for high-quality experimental data. This framework supports the experimental analysis by feeding valuable data back into mAIbe's AI models, thereby enhancing the efficiency and accuracy of antibody development.
The initial phases of the collaboration will focus on accelerating the functional testing of candidate antibodies generated through AI. This approach not only fosters faster validation of these candidates but also facilitates rapid iterations between computational predictions and experimental outcomes. Such a streamlined process lays the groundwork for achieving unprecedented speeds in therapeutic antibody discovery.
The collaboration promises to set a new benchmark in the field, emphasizing agility and innovation through data-driven methodologies. By effectively bridging the gap in lab-based design workflows, mAIbe and LenioBio are poised to introduce a transformative impact on the landscape of antibody development.
About LenioBio: Established in Germany in 2016, LenioBio GmbH specializes in cell-free protein expression through its proprietary ALiCE® platform, which enables rapid protein discovery, development, and scalable production. Headquartered in Düsseldorf, the company operates state-of-the-art R&D and manufacturing facilities in Aachen. To learn more, visit www.leniobio.com or follow LenioBio on LinkedIn.
About mAIbe: Based in Rome, Italy, mAIbe focuses on the design of monoclonal antibodies using AI-driven techniques, combining generative AI informed by physical and synthetic biology principles. The firm is dedicated to developing precise and cost-effective antibodies targeting viral and bacterial pathogens, thereby accelerating the availability of next-generation immunotherapies. For further insights, visit www.maibe.eu.
As the collaboration unfolds, the scientific community eagerly anticipates the breakthrough developments that may arise from this merger of technology and biology. By leveraging each other’s strengths, mAIbe and LenioBio are not just competing in the market but rather setting the stage for future innovation in therapeutic antibody discovery.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.